Publication

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial

ANNÉE

2015

AUTEURS

Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J

CONGRÈS/REVUE

BMC Cancer

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1186/s12885-015-1507-3

Clinical Complete response (CCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer: findings from ACCORD 12/PRODIGE 2 randomized trial

ANNÉE

2015

AUTEURS

Gérard JP, Chamorey E, Gourgou-Bourgade S, Benezery K, de Laroche G, Mahé MA, Boige V, Juzyna B

CONGRÈS/REVUE

Radiother Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.radonc.2015.04.003

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial

ANNÉE

2015

AUTEURS

Lepage C, Phelip JM, Cany L, Faroux R, Manfredi S, Ain JF, Pezet D, Baconnier M, Deguiral P, Terrebone E, Adenis A, Le Malicot K, Bedenne L, Bouche O

CONGRÈS/REVUE

Dig Liver Dis

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/j.dld.2015.03.021

DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

ANNÉE

2015

AUTEURS

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P

CONGRÈS/REVUE

JAMA Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1001/jamaoncol.2015.5392

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

ANNÉE

2014

AUTEURS

Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A, Federation Francophone de Cancerologie Digestive and UNICANCER-GI Group

CONGRÈS/REVUE

Lancet Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/s1470-2045(14)70028-2

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study

ANNÉE

2014

AUTEURS

Chibaudel B, Tournigand C, Bonnetain F, de Larauze MH, de Gramont A, Laurent-Puig P, Louvet C, André T, de Gramont A.

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.tps3648

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study

ANNÉE

2014

AUTEURS

Chibaudel B, Tournigand C, Bonnetain F, de Larauze MH, de Gramont A, Laurent-Puig P, Louvet C, André T, de Gramont A.

CONGRÈS/REVUE

ASCO

LIEN PUBLICATIONS ASSOCIÉES

https://meetings.asco.org/abstracts-presentations/98406/poster

PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial

ANNÉE

2014

AUTEURS

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile J-F, Laurent-Puig P, Lepage C

CONGRÈS/REVUE

Lancet Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/s1470-2045(14)70227-x

Prognostic value of KRAS mutations in stage III colon cancer: post-hoc analysis of the PETACC8 phase III trial dataset

ANNÉE

2014

AUTEURS

Blons H, Emile JF, Le Malicot K, Julié C, Zaanan A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J

CONGRÈS/REVUE

Ann Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1093/annonc/mdu464

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

ANNÉE

2014

AUTEURS

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C

CONGRÈS/REVUE

Lancet Oncol

LIEN PUBLICATIONS ASSOCIÉES

https://doi.org/10.1016/s1470-2045(14)70227-x